Clinical Trials on Chronic Constipation in New Zealand

Total 4049 results

Academy of Nutrition and Dietetics

Completed

Can Dietitians Reduce Interdialytic Weight Gain in at Risk Hemodialysis Patients Through Tailored Education on Dietary Sodium and Fluid Intake?

End Stage Renal Disease Requiring Hemodialysis

New Zealand
Waikato Hospital
Waikato Hospital Research Fund

Completed

Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study (BOLD)

Chronic Obstructive Pulmonary Disease

New Zealand
Intervene, Inc.

Terminated

A Feasibility Study of the ReLeaf Catheter System (ReLeaf)

Chronic Venous Insufficiency

New Zealand
Ferring Pharmaceuticals

Terminated

Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Sweden, Canada, Hungary, United States, Brazil, South Africa, Czech Republic, Germany, Mexico, Poland, Slovakia, United Kingdom
Alios Biopharma Inc.

Terminated

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Hepatitis B | Chronic Hepatitis B | Viral Hepatitis B

New Zealand
Aligos Therapeutics

Terminated

A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

Chronic Hepatitis B

United Kingdom, New Zealand
AbbVie
Ironwood Pharmaceuticals, Inc.

Enrolling by invitation

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Canada, Israel, Netherlands
University of Otago
Health Research Council, New Zealand

Completed

Warm Homes for Elder New Zealanders (WHEZ)

Chronic Obstructive Pulmonary Disease

New Zealand
Alkermes, Inc.

Completed

ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)

Opioid-induced Constipation

United States
Fisher and Paykel Healthcare
Medical Research Institute of New Zealand; Alana Healthcare

Terminated

Nasal High Flow Therapy 30 Day Readmission Study (N3ADS)

Chronic Obstructive Pulmonary Disease | COPD

United States, New Zealand
Gilead Sciences

Completed

Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

Chronic Hepatitis B

United States, New Zealand
Arrow Therapeutics
DDS, Dundee; David Mutimer, Birmingham; Ed Gane, ACS New Zealand

Terminated

A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers (CP104)

Chronic Hepatitis C

New Zealand, United Kingdom
Fisher and Paykel Healthcare

Recruiting

Oxygen Wound Therapy Feasibility Study

Chronic Leg Ulcer

New Zealand
Novartis
Novartis Pharmaceuticals

Completed

Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B

Hepatitis B

Hong Kong, Singapore, New Zealand
GlaxoSmithKline

Completed

Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.

Asthma

Australia, New Zealand
AbbVie
Ironwood Pharmaceuticals, Inc.

Active, not recruiting

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) (LINZESS)

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Belgium, Bulgaria, Canada, Estonia, Israel, Italy, Netherlands, Poland, Puerto Rico, Spain, Ukraine, United Kingdom, Germany
Shionogi

Completed

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

Opioid-induced Constipation

United States
Gilead Sciences

Completed

Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults

Ulcerative Colitis

New Zealand
Synthetic Biologics Inc.

Completed

A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome Characterized by Constipation

United States, Canada
AstraZeneca
Ironwood Pharmaceuticals, Inc.

Completed

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (D5630C00001)

Irritable Bowel Syndrome With Constipation (IBS-C)

United States, Australia, China, New Zealand, Canada
University of Auckland, New Zealand
Leukaemia & Blood Cancer New Zealand

Active, not recruiting

KISS Study: Kinase Inhibition With Sprycel Start up (KISS)

Chronic Myeloid Leukemia

New Zealand
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
University of Auckland, New Zealand
Waitemata District Health Board; Counties Manukau Health

Completed

Randomised Trial of Doppler-Optimised Fluid Balance in Elective Colectomy

Colorectal Cancer | Surgery | Perioperative Care | Colectomy

New Zealand
Ardelyx

Recruiting

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Aligos Therapeutics

Terminated

A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

Chronic Hepatitis B

New Zealand, Bulgaria, Moldova, Republic of, Romania
Innate Immunotherapeutics
National Multiple Sclerosis Society; Primorus Clinical Trials

Completed

Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

New Zealand
Soroka University Medical Center
Eiger BioPharmaceuticals

Active, not recruiting

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection (LOWR6)

Hepatitis D, Chronic

Israel, New Zealand, Turkey
Bausch Health Americas, Inc.
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

Opioid-induced Constipation

United States
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

Hepatitis B, Chronic

New Zealand
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

New Zealand, Poland, France
Hoffmann-La Roche

Completed

A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients

Hepatitis C, Chronic

New Zealand, Australia
GlaxoSmithKline

Completed

Study to Assess GW642444 in Asthma Patients

Pulmonary Disease, Chronic Obstructive

Australia, New Zealand
Ardelyx

Completed

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C (T3MPO-2)

Constipation Predominant Irritable Bowel Syndrome

United States
GlaxoSmithKline

Completed

Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects

Leukaemia, Lymphocytic, Chronic

Australia, United States, New Zealand
Bridge Biotherapeutics, Inc.
Covance

Terminated

Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis

Ulcerative Colitis

New Zealand
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Terminated

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (LIN-MD-63)

Irritable Bowel Syndrome With Constipation

United States, Canada
Alizyme

Terminated

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Constipation-Predominant Irritable Bowel Syndrome

United States
Ironwood Pharmaceuticals, Inc.
Allergan Sales, LLC

Completed

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Allergan
Ironwood Pharmaceuticals, Inc.

Completed

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

Functional Constipation

United States
Eiger BioPharmaceuticals

Completed

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Hepatitis D, Chronic

Israel, New Zealand, Pakistan
Hoffmann-La Roche

Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients

Hepatitis B, Chronic

Hong Kong, Taiwan, New Zealand
Bausch Health Americas, Inc.
Pfizer

Completed

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

Advanced Illness Patients With Opioid Induced Constipation

United States
Ardelyx

Completed

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C (T3MPO-1)

Constipation Predominant Irritable Bowel Syndrome

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Bausch Health Americas, Inc.

Completed

Compassionate Use Study of Methylnaltrexone

Opioid-induced Constipation

United States
ABK Biomedical

Completed

Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC

Metastatic Colorectal Cancer | Liver Cancer | Hepatocellular Carcinoma Non-resectable

New Zealand
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (CIBS)

Irritable Bowel Syndrome Characterized by Constipation

United States
Bausch Health Americas, Inc.

Recruiting

Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) ((IBS-C))

Irritable Bowel Syndrome With Constipation

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, New Zealand

Clinical Trials on Chronic Constipation in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations